Zosano Pharma ZSAN shares are trading lower on Wednesday after the company announced it received a complete response letter from the FDA for its Qtrypta.
Zosano Pharma is a clinical-stage specialty pharmaceutical company. It has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of various indications.
Zosano Pharma shares traded down 27.14% to 45 cents on Wednesday at the time of publication. The stock has a 52-week high of $2.45 and a 52-week low of 40 cents.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
